Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
December 09 2024 - 4:05PM
Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology
company, today announced that Chief Executive Officer Josh Riggs
and Chief Financial Officer Andrea James will attend “J.P. Morgan
Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare
Conference in San Francisco, from January 13-16, 2025. During this
period, Oncocyte will host one-on-one meetings with interested
investors.
Investors wishing to schedule a meeting are encouraged to
contact Julie Silber at PCG Advisory via email at
jsilber@pcgadvisory.com.
Event: “J.P. Morgan
Week”Dates: January 13-16,
2025Location: San Francisco, CA, USA
About OncocyteOncocyte is a
diagnostics technology company. The Company’s tests are designed to
help provide clarity and confidence to physicians and their
patients. VitaGraft™ is a clinical blood-based solid organ
transplantation monitoring test. GraftAssure™ is a research use
only (RUO) blood-based solid organ transplantation monitoring test.
DetermaIO™ is a gene expression test that assesses the tumor
microenvironment to predict response to immunotherapies.
DetermaCNI™ is a blood-based monitoring tool for monitoring
therapeutic efficacy in cancer patients. For more information
about Oncocyte, please visit https://oncocyte.com/. For
more information about our products, please visit the following web
pages:
VitaGraft
Kidney™ – https://oncocyte.com/vitagraft-kidney/VitaGraft
Liver™ – https://oncocyte.com/vitagraft-liver/GraftAssure™ – https://oncocyte.com/graftassure/DetermaIO™ – https://oncocyte.com/determa-io/DetermaCNI™ – https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™
are trademarks of Oncocyte Corporation.
CONTACT:Jeff RamsonPCG Advisory(646)
863-6893jramson@pcgadvisory.com
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Dec 2023 to Dec 2024